All In Biotech

Drug Trial Radar · NCT00232687

A Switch Study of BMS-337039 in Schizophrenic Out-patients

A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, While on Risperidone

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

450

Actual

Start

Jun 1, 2005

Primary completion

Apr 1, 2007

Study completion Apr 1, 2007

Sponsor

Sponsor type
Industry
Collaborators
Otsuka America Pharmaceutical
First posted
Oct 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing efficacy and/or safety/tolerability issues while on risperidone.

Conditions

  • Schizophrenia

Interventions

  • AripiprazoleDrug

    Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.

  • AripiprazoleDrug

    Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients who discontinue because of Adverse EventsTime frame: Up to 22 months

Locations

72 sites in 10 countries. Site status is shown where the registry gives one.

  • Local Institution

    Hall in Tirol, Austria

  • Local Institution

    Vienna, Austria

  • Local Institution

    Bruges, Belgium

  • Local Institution

    Brussels, Belgium

  • Local Institution

    Diest, Belgium

  • Local Institution

    Halle, Belgium

  • Local Institution

    Sint-Denijs-Westrem, Belgium

  • Local Institution

    Stokrooie, Belgium

  • Local Institution

    Havířov, Czechia

  • Local Institution

    Olomouc, Czechia

  • Local Institution

    Prague, Czechia

  • Local Institution

    Přerov, Czechia

  • Local Institution

    Aubagne, France

  • Local Institution

    Bordeaux, France

  • Local Institution

    Brumath, France

  • Local Institution

    Château-Gontier, France

  • Local Institution

    Clermont-Ferrand, France

  • Local Institution

    Dijon, France

  • Local Institution

    Dommartin-lès-Toul, France

  • Local Institution

    Fains-Véel, France

  • Local Institution

    Hénin-Beaumont, France

  • Local Institution

    Le Pecq, France

  • Local Institution

    Lyon, France

  • Local Institution

    Poitiers, France

  • Local Institution

    Reims, France

  • Local Institution

    Roubaix, France

  • Local Institution

    Toulon, France

  • Local Institution

    Toulouse, France

  • Local Institution

    Achim, Germany

  • Local Institution

    Bochum, Germany

  • Local Institution

    Cologne, Germany

  • Local Institution

    Ellwangen, Germany

  • Local Institution

    Hattingen, Germany

  • Local Institution

    Nuremberg, Germany

  • Local Institution

    Osnabrück, Germany

  • Local Institution

    Ostfildern, Germany

  • Local Institution

    Witten, Germany

  • Local Institution

    Athens, Greece

  • Local Institution

    Chania, Greece

  • Local Institution

    Corfu, Greece

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.